You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
恆瑞醫藥(600276.SH):塞來昔布膠囊獲藥品註冊批件
格隆匯 12-06 16:30

格隆匯12月6日丨恆瑞醫藥(600276.SH)公佈,公司近日收到國家藥品監督管理局(“藥監局”)核准簽發的《藥品註冊批件》,藥品名稱為塞來昔布膠囊。

2017717日,恆瑞醫藥向江蘇省食品藥品監督管理局遞交的藥品註冊申請獲得受理。塞來昔布是一種選擇性抑制COX-2的非甾體抗炎藥,主要適用於緩解骨關節炎、成人類風濕關節炎和強直性脊柱炎的症狀和體徵,以及治療成人性疼痛。

塞來昔布膠囊由GD Searle和輝瑞開發,最早於1998年在美國獲批上市,商品名為CELEBREX,截止目前,本品已在歐盟多個國家獲批上市;2012年原研在中國獲批上市,商品名為西樂葆,規格為0.1g0.2g。目前國內已有包括齊魯、石藥歐意多家申報生產,除恆瑞外,未見其他獲批信息,恆瑞為國內首家獲批仿製塞來昔布膠囊的企業。經查詢,2018年該產品全球銷售額約為6.78億美元,中國銷售額約為8633萬美元。

截至目前,該產品項目已投入研發費用約為1752萬元人民幣。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account